Interim results from MaxCyte are due on 27th September. Our FY 2016 estimates assume revenue growth of 31%, in line with the H1 performance reported in the trading update. We expect the company to report on investment the Drug Discovery division post the IPO and increasing interest in the application of its flow electroporation technology in Cell Therapy. We maintain our BUY recommendation and 170p target price ahead of the results.
